Computational Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States
Nadeem Riaz
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, United States
Judy Sarungbam
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, United States
Satish K Tickoo
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, United States
Hikmat A Al-Ahmadie
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, United States
William Lee
Computational Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, United States
Venkatraman E Seshan
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, United States
A Ari Hakimi
Computational Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, United States
Chris Sander
Computational Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States
Mutations, deletions, and changes in copy number of mitochondrial DNA (mtDNA), are observed throughout cancers. Here, we survey mtDNA copy number variation across 22 tumor types profiled by The Cancer Genome Atlas project. We observe a tendency for some cancers, especially of the bladder, breast, and kidney, to be depleted of mtDNA, relative to matched normal tissue. Analysis of genetic context reveals an association between incidence of several somatic alterations, including IDH1 mutations in gliomas, and mtDNA content. In some but not all cancer types, mtDNA content is correlated with the expression of respiratory genes, and anti-correlated to the expression of immune response and cell-cycle genes. In tandem with immunohistochemical evidence, we find that some tumors may compensate for mtDNA depletion to sustain levels of respiratory proteins. Our results highlight the extent of mtDNA copy number variation in tumors and point to related therapeutic opportunities.